Get the Stockscreener App
14.60
4.95%
-0.76
Promis Neurosciences Inc stock is traded at $14.60, with a volume of 11,173.
It is down -4.95% in the last 24 hours and up +19.67% over the past month.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.
See More
Previous Close:
$15.36
Open:
$15.21
24h Volume:
11,173
Relative Volume:
0.14
Market Cap:
$129.85M
Revenue:
-
Net Income/Loss:
$-40.62M
P/E Ratio:
-0.7523
EPS:
-19.4076
Net Cash Flow:
$-35.63M
1W Performance:
-0.41%
1M Performance:
+19.67%
6M Performance:
-30.01%
1Y Performance:
+6.38%
1-Day Range:
$14.40
$15.21
1-Week Range:
$14.23
$15.46
52-Week Range:
$6.27
$27.40
Promis Neurosciences Inc Stock (PMN) Company Profile
Name
Promis Neurosciences Inc
Sector
Industry
Phone
416-847-6898
Address
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
14.48 | 133.71M | 0 | -40.62M | -35.63M | -19.41 |
VRTX
Vertex Pharmaceuticals Inc
|
549.89 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
820.43 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,052.79 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
146.75 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
211.27 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Promis Neurosciences Inc Stock (PMN) Latest News
ProMIS Neurosciences PMN310 shows early Alzheimer's promise - scanx.trade
PMN310 shows dose-dependent reduction of amyloid-beta oligomers - scanx.trade
ProMIS (PMN) Earnings Update: The EPS Result Is Above Expectation in Latest Trading; Price Move: The Stock Records a 0.13% Increase in the Latest SessionEarnings Manipulation Risk - vinanet.vn
Q3 EPS Estimates for PMN Raised by Brookline Capital Markets - MarketBeat
ProMIS Neurosciences (PMN) Q2 2026 Update Highlights Strong Cash Position Amid High Valuation - GuruFocus
Maxim Group Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Maintains Target Price $35 - Moomoo
ProMIS Neurosciences (PMN) Holds Near $14.86 as Traders Eye Key Resistance at $15.60Momentum Breakout Ideas - Vinanet
Roth Capital initiates coverage on ProMIS Neurosciences with Buy rating - scanx.trade
PMN Maintained by Guggenheim -- Price Target Raised to $100 - GuruFocus
Guggenheim Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $100 - Moomoo
ProMIS Neurosciences Inc. Stock 12‑Month Price Target Raised to $43.64, Implies 195% Upside - TradingView
Promis Neurosciences (NASDAQ:PMN) Stock Price Expected to Rise, Guggenheim Analyst Says - MarketBeat
ProMIS Neurosciences (PMN): Great Point group reports 7.66% beneficial stake - Stock Titan
Chardan Capital Maintains ProMIS Neurosciences(PMN.US) With Buy Rating, Raises Target Price to $33 - Moomoo
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and ... By GuruFocus - Investing.com Canada
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlight - GuruFocus
Promis Neurosciences Q2 Earnings Call Highlights - MarketBeat
ProMIS Neurosciences (PMN) Climbs 2.00% to $14.79, Approaching Key Resistance at $15.53Turnaround Stocks - vinanet.vn
PROMIS NEUROSCIENCES ($PMN) Releases Q2 2026 Earnings - Quiver Quantitative
Earnings call transcript: ProMIS Neurosciences posts strong cash position in Q2 2026 - Investing.com Canada
PMN: Interim phase I-B data for PMN310 showed no ARIA-E and strong biomarker signals, with cash runway through 2027 - TradingView
ProMIS Neurosciences Q2 Results: Cash Runway Extends To 2027 - scanx.trade
Promis Neurosciences (NASDAQ:PMN) Issues Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
ProMIS Neurosciences (PMN) gets 7.77% stake disclosure by Wellington fund - Stock Titan
ProMIS Neurosciences Inc. Q2 2026: Net loss $(11.73)M, Diluted EPS $(1.28) — 10-Q Summary - TradingView
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights - The Manila Times
ProMIS Neurosciences (PMN) extends cash runway with $70.1M PIPE amid higher R&D - Stock Titan
ProMIS Neurosciences (PMN): Wellington group discloses 7.77% ownership stake - Stock Titan
ProMIS Neurosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ProMIS Neurosciences Inc expected to post a loss of $1.38 a shareEarnings Preview - TradingView
ProMIS Neurosciences Inc (PMN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insider at ProMIS Neurosciences (PMN) buys 2,280 common shares - Stock Titan
ProMIS Neurosciences Inc (PMN) Stock News Today - TradingKey
Promis Neurosciences (NASDAQ:PMN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Promis Neurosciences (PMN) Projected to Post Earnings on Thursday - MarketBeat
Janus Henderson Group PLC Acquires New Position in Promis Neurosciences $PMN - MarketBeat
ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026 - The Manila Times
ProMIS schedules 4:30 p.m. webcast for Aug. 13 update - Stock Titan
ProMIS Neurosciences (PMN) Shares Drop 8% as Stock Tests Key Support LevelETF AUM Growth - vinanet.vn
ADAR1 Capital Management LLC Buys Shares of 95,350 Promis Neurosciences $PMN - MarketBeat
Promis Neurosciences (NASDAQ:PMN) Upgraded at Chardan Capital - MarketBeat
PMN Maintains Buy Rating by Chardan Capital -- Price Target Rais - GuruFocus
Chardan raises ProMIS Neurosciences stock price target on trial data By Investing.com - Investing.com Canada
Chardan Adjusts Price Target on ProMIS Neurosciences to $33 From $20, Maintains Buy Rating - marketscreener.com
ProMIS Neurosciences (PMN) Reports Promising Interim Biomarker D - GuruFocus
Why is ProMIS Neurosciences stock surging today? By Investing.com - Investing.com Canada
ProMIS Neurosciences (PMN) Surges 21.3% Pre-Market Ahead of Earn - GuruFocus
ProMIS Neurosciences Says PMN310 Alzheimer Drug Shows Positive Interim Safety, Biomarker Data - marketscreener.com
ProMIS Neurosciences (PMN) Reports Promising Interim Biomarker Data Amid High Valuation Expectations - GuruFocus
ProMIS Neurosciences Inc. Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in PRECISE-AD Phase 1b Alzheimer?s Disease Trial - marketscreener.com
Promis Neurosciences Inc Stock (PMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.47%
0.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):